Roche Holding AG - Bearer Shares RO

SWX: RO | ISIN: CH0012032113   30/05/2025
280,00 CHF (+1,08%)
(+1,08%)   30/05/2025

30 mei 2025 · Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis · Persbericht

23 mei 2025 · CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer · Persbericht

23 mei 2025 · Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology · Persbericht

23 mei 2025 · New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients · Persbericht

22 mei 2025 · FDA approves Roche’s Susvimo for diabetic retinopathy · Persbericht

20 mei 2025 · Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma · Persbericht

14 mei 2025 · Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis · Persbericht

13 mei 2025 · Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer · Persbericht

6 mei 2025 · Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity · Persbericht

30 april 2025 · CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings · Persbericht

29 april 2025 · Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer · Persbericht

25 april 2025 · New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission · Persbericht

24 april 2025 · [Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter · Persbericht

23 april 2025 · Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS) · Persbericht

22 april 2025 · Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years · Persbericht

14 april 2025 · European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy · Persbericht

3 april 2025 · Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025 · Persbericht

2 april 2025 · Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis · Persbericht

25 maart 2025 · Roche Annual General Meeting 2025 · Persbericht

25 maart 2025 · Assemblée générale 2025 de Roche · Persbericht

Mijn selecties